These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Gene editing prospects for treating inherited retinal diseases. Benati D; Patrizi C; Recchia A J Med Genet; 2020 Jul; 57(7):437-444. PubMed ID: 31857428 [TBL] [Abstract][Full Text] [Related]
6. Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model. Karaosmanoglu B; Imren G; Utine E; Taylan Sekeroglu H; Taskiran EZ Exp Eye Res; 2024 Apr; 241():109833. PubMed ID: 38369231 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes. Lavrovsky Y; Chen S; Roy AK Biochem Mol Med; 1997 Oct; 62(1):11-22. PubMed ID: 9367793 [TBL] [Abstract][Full Text] [Related]
12. A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets. Yau EH; Butler MC; Sullivan JM Exp Eye Res; 2016 Oct; 151():236-55. PubMed ID: 27233447 [TBL] [Abstract][Full Text] [Related]
13. RNA-targeting strategies as a platform for ocular gene therapy. Kumar S; Fry LE; Wang JH; Martin KR; Hewitt AW; Chen FK; Liu GS Prog Retin Eye Res; 2023 Jan; 92():101110. PubMed ID: 35840489 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic antisense and ribozymes. Rossi JJ Br Med Bull; 1995 Jan; 51(1):217-25. PubMed ID: 7767645 [TBL] [Abstract][Full Text] [Related]
15. Guiding Lights in Genome Editing for Inherited Retinal Disorders: Implications for Gene and Cell Therapy. Sanjurjo-Soriano C; Kalatzis V Neural Plast; 2018; 2018():5056279. PubMed ID: 29853845 [TBL] [Abstract][Full Text] [Related]
16. Prospects for nucleic acid-based therapeutics against hepatitis C virus. Lee CH; Kim JH; Lee SW World J Gastroenterol; 2013 Dec; 19(47):8949-62. PubMed ID: 24379620 [TBL] [Abstract][Full Text] [Related]